Diaceutics PLC
DXRX.L · LSE
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | £14,564 | £19,838 | £12,320 | £13,775 |
| % Growth | -26.6% | 61% | -10.6% | – |
| Cost of Goods Sold | £2,477 | £2,299 | £3,707 | £2,769 |
| Gross Profit | £12,087 | £17,539 | £8,613 | £11,006 |
| % Margin | 83% | 88.4% | 69.9% | 79.9% |
| R&D Expenses | £0 | £0 | £0 | £0 |
| G&A Expenses | £15,435 | £16,418 | £14,324 | £11,911 |
| SG&A Expenses | £15,435 | £16,418 | £12,206 | £11,911 |
| Sales & Mktg Exp. | £0 | £0 | £0 | £0 |
| Other Operating Expenses | -£169 | -£9 | £0 | -£53 |
| Operating Expenses | £15,266 | £16,409 | £12,206 | £11,858 |
| Operating Income | -£3,348 | £1,130 | -£3,593 | -£845 |
| % Margin | -23% | 5.7% | -29.2% | -6.1% |
| Other Income/Exp. Net | £295 | £226 | £329 | £362 |
| Pre-Tax Income | -£3,053 | £1,356 | -£3,264 | -£483 |
| Tax Expense | -£652 | £475 | -£680 | -£222 |
| Net Income | -£2,401 | £881 | -£2,584 | -£261 |
| % Margin | -16.5% | 4.4% | -21% | -1.9% |
| EPS | -0.028 | 0.01 | -0.031 | -0.003 |
| % Growth | -373.1% | 134% | -887.1% | – |
| EPS Diluted | -0.028 | 0.01 | -0.031 | -0.003 |
| Weighted Avg Shares Out | 42,271 | 84,728 | 84,451 | 84,194 |
| Weighted Avg Shares Out Dil | 84,542 | 84,456 | 84,451 | 84,227 |
| Supplemental Information | – | – | – | – |
| Interest Income | £195 | £252 | £349 | £393 |
| Interest Expense | £29 | £26 | £28 | £24 |
| Depreciation & Amortization | £1,838 | £2,905 | £2,275 | £2,840 |
| EBITDA | -£1,341 | £4,035 | -£961 | £2,339 |
| % Margin | -9.2% | 20.3% | -7.8% | 17% |